These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38662870)

  • 1. Linkage of cell division cycle 42 with clinical features, treatment response and survival in adult Philadelphia chromosome negative acute lymphoblastic leukemia.
    Chen Q; Zhu X; He D; Ding W
    Scand J Clin Lab Invest; 2024 May; 84(3):139-146. PubMed ID: 38662870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Short NJ; Kantarjian HM; Sasaki K; Cortes JE; Ravandi F; Thomas DA; Garcia-Manero G; Khouri I; Kebriaei P; Champlin RE; Pierce S; Issa GC; Konopleva M; Kadia TM; Bueso-Ramos C; Khoury JD; Jain N; O'Brien SM; Jabbour E
    Cancer; 2016 Dec; 122(24):3812-3820. PubMed ID: 27508525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Yoon JH; Yhim HY; Kwak JY; Ahn JS; Yang DH; Lee JJ; Kim SJ; Kim JS; Park SJ; Choi CW; Eom HS; Park SK; Choi SY; Kim SH; Kim DW; Lee S
    Ann Oncol; 2016 Jun; 27(6):1081-1088. PubMed ID: 26951627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EIF3B Associates with Exacerbated Clinical Features, Poor Treatment Response and Survival in Adult Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Patients.
    Zhu F; Fu Y; He X
    Technol Cancer Res Treat; 2021; 20():15330338211041464. PubMed ID: 34617851
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
    Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
    J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO).
    Candoni A; Rambaldi A; Fanin R; Velardi A; Arcese W; Ciceri F; Lazzarotto D; Lussana F; Olivieri J; Grillo G; Parma M; Bruno B; Sora F; Bernasconi P; Saccardi R; Foà R; Sessa M; Bresciani P; Giglio F; Picardi A; Busca A; Sica S; Perruccio K; Zucchetti E; Diral E; Iori AP; Colombo AA; Tringali S; Santarone S; Irrera G; Mancini S; Zallio F; Malagola M; Albano F; Carella AM; Olivieri A; Tecchio C; Dominietto A; Vacca A; Sorasio R; Orciuolo E; Risitano AM; Leotta S; Cortelezzi A; Mammoliti S; Oldani E; Bonifazi F;
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2388-2397. PubMed ID: 31400502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
    Zhang M; Fu H; Lai X; Tan Y; Zheng W; Shi J; Zhao Y; Lin M; He J; Cai Z; Luo Y; Huang H
    PLoS One; 2016; 11(10):e0163599. PubMed ID: 27695097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of clinical utility of MRD assessment with different techniques on survival in acute B lymphoblastic leukemia.
    Huang A; Huang C; Tang G; Cheng H; Liu M; Ding J; Gong S; Chen Q; Zhang W; Yang J; Wang J; Hu X
    Leuk Lymphoma; 2018 May; 59(5):1073-1083. PubMed ID: 28857648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia.
    Nagafuji K; Miyamoto T; Eto T; Ogawa R; Okumura H; Takase K; Kawano N; Miyazaki Y; Fujisaki T; Wake A; Ohno Y; Kurokawa T; Kamimura T; Takamatsu Y; Yokota S; Akashi K
    Eur J Haematol; 2019 Sep; 103(3):164-171. PubMed ID: 31132205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
    Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
    Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia.
    Motlló C; Ribera JM; Morgades M; Granada I; Montesinos P; Mercadal S; González-Campos J; Moreno MJ; Barba P; Cervera M; Barrios M; Novo A; Bernal T; Hernández-Rivas JM; Abella E; Amigo ML; Tormo M; Martino R; Lavilla E; Bergua J; Serrano A; García-Belmonte D; Guàrdia R; Grau J; Feliu E;
    Leuk Lymphoma; 2018 Jan; 59(1):146-154. PubMed ID: 28554259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
    Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
    Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lou Y; Ma Y; Li C; Suo S; Tong H; Qian W; Mai W; Meng H; Yu W; Mao L; Wei J; Xu W; Jin J
    Front Med; 2017 Jun; 11(2):229-238. PubMed ID: 28349299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of minimal residual disease in young adults with standard-risk/Ph-negative precursor B-acute lymphoblastic leukemia: results of prospective study.
    Salah-Eldin M; Abousamra NK; Azzam H
    Med Oncol; 2014 May; 31(5):938. PubMed ID: 24692146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study).
    Nagafuji K; Miyamoto T; Eto T; Kamimura T; Taniguchi S; Okamura T; Ohtsuka E; Yoshida T; Higuchi M; Yoshimoto G; Fujisaki T; Abe Y; Takamatsu Y; Yokota S; Akashi K; Harada M
    J Hematol Oncol; 2013 Feb; 6():14. PubMed ID: 23388549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD20 positivity and white blood cell count predict treatment outcomes in Philadelphia chromosome-negative acute lymphoblastic leukemia patients ineligible for pediatric-inspired chemotherapy.
    Isshiki Y; Ohwada C; Sakaida E; Onoda M; Aotsuka N; Tanaka H; Fukazawa M; Cho R; Sugawara T; Kawaguchi T; Hara S; Yokota A
    Jpn J Clin Oncol; 2017 Nov; 47(11):1047-1054. PubMed ID: 28973362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.
    Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1611-1620. PubMed ID: 30537550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia.
    Ribera JM; Morgades M; Ciudad J; Montesinos P; Esteve J; Genescà E; Barba P; Ribera J; García-Cadenas I; Moreno MJ; Martínez-Carballeira D; Torrent A; Martínez-Sánchez P; Monsalvo S; Gil C; Tormo M; Artola MT; Cervera M; González-Campos J; Rodríguez C; Bermúdez A; Novo A; Soria B; Coll R; Amigo ML; López-Martínez A; Fernández-Martín R; Serrano J; Mercadal S; Cladera A; Giménez-Conca A; Peñarrubia MJ; Abella E; Vall-Llovera F; Hernández-Rivas JM; Garcia-Guiñon A; Bergua JM; de Rueda B; Sánchez-Sánchez MJ; Serrano A; Calbacho M; Alonso N; Méndez-Sánchez JÁ; García-Boyero R; Olivares M; Barrena S; Zamora L; Granada I; Lhermitte L; Feliu E; Orfao A
    Blood; 2021 Apr; 137(14):1879-1894. PubMed ID: 33150388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Akahoshi Y; Nishiwaki S; Mizuta S; Ohashi K; Uchida N; Tanaka M; Fukuda T; Ozawa Y; Takahashi S; Onizuka M; Shiratori S; Nakamae H; Kanda Y; Ichinohe T; Atsuta Y; Kako S;
    Cancer Sci; 2019 Oct; 110(10):3255-3266. PubMed ID: 31402561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.